Clinical Research Directory

Inclusion criteria： * A clear history of acetaminophen (or acetaminophen-containing drugs) ingestion. * Plasma and/or urine testing for acetaminophen components if history of ingestion is unclear. * Monitoring of Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 1000 IU/L at any time after APAP administration and Roussel Uclaf Causality Assessment Method(RUCAM) score \> 6 * Age ≥ 14 years old * The subject or guardian agrees to participate in this project and signs an informed consent form. Exclusion criteria： * The use of drugs for which frequency of adverse reactions to liver damage is defined as "common or very common" (≥1%) in the instructions. * Concurrent use of herbs that are clearly susceptible to liver damage (see list of definitions in the Annex). * Have a known definite cause of liver damage: active viral hepatitis; alcoholic liver disease; autoimmune liver disease; primary or secondary liver tumors; and other underlying liver disease that has affected liver function. * Those who fail to provide complete general information and clinical information. * Subjects or guardians who do not agree to see this project do not sign the informed consent form.